These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15480911)

  • 1. Patients with rheumatoid arthritis (RA) and proteinuria.
    Urata Y
    Clin Exp Nephrol; 2004 Sep; 8(3):288; author reply 289; discussion 290. PubMed ID: 15480911
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunopharmacological evaluation of bucillamine in rheumatoid arthritis.
    Matsuno H; Kitano T; Matsushita I; Tsuji H; Ochiai H
    Drugs Exp Clin Res; 1993; 19(5):205-11. PubMed ID: 8174492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].
    Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug-induced renal disorders in patients with rheumatoid arthritis].
    Nakano M; Nishi S; Ueno M; Saito T; Hasegawa H; Arakawa M
    Ryumachi; 1996 Oct; 36(5):775-82. PubMed ID: 8969558
    [No Abstract]   [Full Text] [Related]  

  • 5. Membranous glomerulonephritis in patients with rheumatoid arthritis.
    Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T
    Clin Ther; 1994; 16(6):1000-6. PubMed ID: 7697679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and treatment of bucillamine-induced nephropathy.
    Hoshino J; Ubara Y; Hara S; Suwabe T; Sawa N; Tagami T; Katori H; Takemoto F; Hara S; Takaichi K
    Nephron Clin Pract; 2006; 104(1):c15-9. PubMed ID: 16685139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis.
    Obayashi M; Uzu T; Harada T; Yamato M; Takahara K; Yamauchi A
    Clin Exp Nephrol; 2003 Dec; 7(4):275-8. PubMed ID: 14712356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis.
    Nobunaga M; Yasuda M
    Agents Actions Suppl; 1993; 44():105-9. PubMed ID: 8372720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Yellow nail syndrome" and rheumatoid arthritis.
    Ichikawa Y; Shimizu H; Arimori S
    Tokai J Exp Clin Med; 1991 Dec; 16(5-6):203-9. PubMed ID: 1820660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bucillamine induces membranous glomerulonephritis.
    Nagahama K; Matsushita H; Hara M; Ubara Y; Hara S; Yamada A
    Am J Kidney Dis; 2002 Apr; 39(4):706-12. PubMed ID: 11920335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of rapidly progressive glomerulonephritis associated with bucillamine-treated rheumatoid arthritis.
    Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T; Fujinami T
    Am J Kidney Dis; 1992 Oct; 20(4):411-3. PubMed ID: 1415212
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug eruption due to bucillamine.
    Kimura M; Kawada A
    Contact Dermatitis; 1998 Aug; 39(2):98-9. PubMed ID: 9746202
    [No Abstract]   [Full Text] [Related]  

  • 13. Yellow nail induced by bucillamine.
    Ishizaki C; Sueki H; Kohsokabe S; Nishida H
    Int J Dermatol; 1995 Jul; 34(7):493-4. PubMed ID: 7591416
    [No Abstract]   [Full Text] [Related]  

  • 14. [A case of rheumatoid arthritis associated with agranulocytosis during bucillamine treatment].
    Negishi M; Yamazaki J; Hosaka M; Iwabuchi H; Matsuda A; Kanemitsu H; Hiramatsu K; Kaga S; Hashimoto M; Kasama T
    Ryumachi; 1994 Jun; 34(3):651-5. PubMed ID: 8052932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis.
    Yoshida A; Morozumi K; Suganuma T; Sugito K; Ikeda M; Oikawa T; Fujinami T; Takeda A; Koyama K
    Am J Nephrol; 1991; 11(4):284-8. PubMed ID: 1799186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine].
    Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H
    Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of non-steroidal anti-inflammatory agents on kidney function in patients with rheumatoid arthritis].
    Dvorkin EB; Murav'ev IuV
    Revmatologiia (Mosk); 1991; (2):28-30. PubMed ID: 1925261
    [No Abstract]   [Full Text] [Related]  

  • 18. [Bucillamin induced lung injury in rheumatoid arthritis].
    Inokuma S; Ikoma T; Inoue S; Ueda A; Urano Y; Satou T; Sayama T; Shimizu H; Hayakawa M; Negishi M
    Ryumachi; 1996 Feb; 36(1):34-42. PubMed ID: 8711536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bucillamine-induced dermatomyositis-like clinical features in a patient with rheumatoid arthritis].
    Takeda T; Shimizu Y; Takeuchi M; Hashimoto S; Nagai C; Uchiyama S; Iwata M
    Rinsho Shinkeigaku; 2005 Jan; 45(1):45-8. PubMed ID: 15715001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of rheumatoid arthritis with bucillamine-induced myasthenia gravis treated by immunoadsorption therapy].
    Sawa N; Ubara Y; Hara S; Hideyuki K; Tagami T; Yokoyama K; Takemoto F; Yamada A; Mori T; Mikami A; Tachibana S; Nakase K
    Ryumachi; 1999 Feb; 39(1):33-8. PubMed ID: 10332215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.